LSV Asset Management Makes New $462,000 Investment in Pacira BioSciences, Inc. (NASDAQ:PCRX)

LSV Asset Management bought a new position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) during the second quarter, Holdings Channel reports. The fund bought 16,133 shares of the company’s stock, valued at approximately $462,000.

A number of other institutional investors have also recently added to or reduced their stakes in PCRX. National Bank of Canada FI acquired a new position in shares of Pacira BioSciences in the 4th quarter worth approximately $966,000. Charles Schwab Investment Management Inc. lifted its position in shares of Pacira BioSciences by 3.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 371,666 shares of the company’s stock worth $12,540,000 after purchasing an additional 11,696 shares during the period. QRG Capital Management Inc. lifted its position in shares of Pacira BioSciences by 11.2% in the 4th quarter. QRG Capital Management Inc. now owns 15,987 shares of the company’s stock worth $539,000 after purchasing an additional 1,610 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Pacira BioSciences by 1.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,411,767 shares of the company’s stock worth $47,633,000 after purchasing an additional 17,949 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Pacira BioSciences by 30.0% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,632 shares of the company’s stock worth $213,000 after purchasing an additional 1,529 shares during the period. 99.73% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Pacira BioSciences news, insider Jonathan Slonin sold 2,836 shares of the company’s stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $28.25, for a total transaction of $80,117.00. Following the transaction, the insider now owns 95,557 shares in the company, valued at $2,699,485.25. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Pacira BioSciences news, CEO Frank D. Lee acquired 8,264 shares of the company’s stock in a transaction on Monday, August 12th. The shares were acquired at an average cost of $12.10 per share, with a total value of $99,994.40. Following the completion of the acquisition, the chief executive officer now directly owns 107,784 shares in the company, valued at $1,304,186.40. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Jonathan Slonin sold 2,836 shares of the company’s stock in a transaction dated Tuesday, July 2nd. The shares were sold at an average price of $28.25, for a total transaction of $80,117.00. Following the sale, the insider now directly owns 95,557 shares in the company, valued at $2,699,485.25. The disclosure for this sale can be found here. Over the last 90 days, insiders have acquired 11,176 shares of company stock worth $136,240. Insiders own 6.40% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on PCRX shares. Raymond James downgraded shares of Pacira BioSciences from an “outperform” rating to a “market perform” rating in a research report on Monday, August 12th. Truist Financial downgraded shares of Pacira BioSciences from a “buy” rating to a “sell” rating and dropped their price target for the stock from $30.00 to $8.00 in a research report on Tuesday, August 13th. Royal Bank of Canada downgraded shares of Pacira BioSciences from an “outperform” rating to a “sector perform” rating and dropped their target price for the company from $37.00 to $14.00 in a research report on Monday, August 12th. JPMorgan Chase & Co. reiterated an “underweight” rating and set a $10.00 target price (down previously from $45.00) on shares of Pacira BioSciences in a research report on Monday, August 12th. Finally, StockNews.com downgraded shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 12th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $24.78.

Pacira BioSciences Stock Performance

PCRX opened at $12.73 on Friday. The company has a current ratio of 6.82, a quick ratio of 5.70 and a debt-to-equity ratio of 0.67. The company’s fifty day moving average price is $17.31 and its two-hundred day moving average price is $24.67. Pacira BioSciences, Inc. has a 1-year low of $11.16 and a 1-year high of $35.95. The company has a market cap of $592.53 million, a price-to-earnings ratio of 8.90 and a beta of 0.84.

Pacira BioSciences (NASDAQ:PCRX) last released its quarterly earnings data on Tuesday, July 30th. The company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.53 by $0.11. Pacira BioSciences had a net margin of 9.21% and a return on equity of 13.22%. The firm had revenue of $178.02 million for the quarter, compared to the consensus estimate of $173.31 million. On average, analysts expect that Pacira BioSciences, Inc. will post 2.24 EPS for the current fiscal year.

Pacira BioSciences Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.